Evaluating triptorelin as a treatment option for breast cancer

References

• Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053–2065.
   PubMed Web of Science ®Google Scholar
• Shupnik MA. Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone1. Biol Reprod. 2005;54(2):279–286.
   Google Scholar
• Highlights of prescribing information of triptorelin pamoate for injectable suspension. [cited 2019 Jul]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf.
   Google Scholar
• EMA. European public MRL assessment report (EPMAR) summary of the scientific discussion for the establishment of. Ema/Cvmp/380257/2014. 2014;44(19):0–18. [cited 2019 Jul].
   Google Scholar
• Triptorelin on U.S. National Library of Medicine, National Center for Biotechnology Information. [cited 2019 Jul]. https://pubchem.ncbi.nlm.nih.gov/compound/triptorelin.
   Google Scholar
• Santen RJ, Manni A, Harvey H. Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res Treat. 1986;7(3):129–145.
   PubMed Web of Science ®Google Scholar
• Blankenstein MA, Henkelman MS, Klijn JGM. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol. 1985;21(12):1493–1499.
   PubMedGoogle Scholar
• Miller WR, Scott WN, Morris R. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985;313(5999):231–233.
   PubMed Web of Science ®Google Scholar
• Gründker C, Völker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein αI-mediated activation of phosphotyrosine phosphatase. Endocrinology. 2001;142(6):2369–2380.
   PubMed Web of Science ®Google Scholar
• Bellet M, Gray KP, Francis PA, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016;34(14):1584–1593.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Triptorelin: a review of its use as an adjuvant anticancer therapy in early breast cancer. Drugs. 2017;77(18):2037–2048.
   PubMed Web of Science ®Google Scholar
• Characteristic triptorelin drug. [cited 2019 Jul]. https://www.drugbank.ca/drugs/DB06825.
   Google Scholar
• Boccardo F, Rubagotti A, Perrotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol Off J Eur Soc Med Oncol. 1994;5(4):337–342.
   PubMed Web of Science ®Google Scholar
• Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16:994–999.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German zoladex trial group. J Clin Oncol. 1989;7:1113–1119.
   PubMed Web of Science ®Google Scholar
• Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001 Jan 15;19(2):343–353.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339(8784):1–15.
   PubMed Web of Science ®Google Scholar
• Sharma R, Beith J, Hamilton A. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer. Breast. 2005;14(3):181–191.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analisys of of four randomized trials. Lancet. 2007;19:1711–1723.
   Google Scholar
• Colleoni M. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international breast cancer study group trial 13–93. J Clin Oncol. 2006;24(9):1332–1341.
   PubMed Web of Science ®Google Scholar
• Roché H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French adjuvant study group 06 randomised trial. Ann Oncol. 2006;17(8):1221–1227.
   PubMed Web of Science ®Google Scholar
• Castiglione-Gertsch M, O'Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003 Dec 17;95(24):1833–1846.
   Google Scholar
• Davidson NE, O’Neill AVA, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node–positive, steroid hormone receptor–positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005;23:5973–5982.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Lê MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005;16(3):389–396.
   PubMed Web of Science ®Google Scholar
• Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006;42(7):895–904.
   PubMed Web of Science ®Google Scholar
• Ciruelos E, Bellet M, Bonnefoi HR, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436–446.
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. Cancer Lett. 2015;371(2):107–118.
   PubMedGoogle Scholar
• Regan MM, Pagani O, Fleming GF, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013;22(6):1094–1100.
   PubMed Web of Science ®Google Scholar
• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–137.
   PubMed Web of Science ®Google Scholar
• Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016 Jul 1;34(19):2221-2231.
   Web of Science ®Google Scholar
• Francis PA, Regan MMFG. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436–446.
   PubMed Web of Science ®Google Scholar
• Saha P, Regan MM, Pagani O, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol. 2017;35(27):3113–3122.
   PubMed Web of Science ®Google Scholar
• Noh WC, Lee Jong W, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study. ABSTRACT 502. J Clin Oncol. 2018 May 20;36(15_suppl):502-502. DOI:10.1200/JCO.2018.36.15_suppl.502.
   Web of Science ®Google Scholar
• Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–858.
   PubMed Web of Science ®Google Scholar
• Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151–1156.
   PubMed Web of Science ®Google Scholar
• Moore HCF, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. Obstet Gynecol Surv. 2015;70(6):392–393.
   Web of Science ®Google Scholar
• Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. J Am Med Assoc. 2011;306(3):269–276.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival a randomized clinical trial. J Am Med Assoc. 2015;314(24):2632–2640.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data. J Clin Oncol. 2018;36(19):1981–1990.
   PubMed Web of Science ®Google Scholar
• Gerber B, Von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334–2341.
   PubMed Web of Science ®Google Scholar
• Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(5):533–538.
   PubMed Web of Science ®Google Scholar
• Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage. Obstet Gynecol. 2015;121(1):78–86.
   Web of Science ®Google Scholar
• Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the anglo celtic group OPTION trial. Ann Oncol. 2017;28(8):1811–1816.
   PubMed Web of Science ®Google Scholar
• Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.
   PubMed Web of Science ®Google Scholar
• Peccatori FA, Azim JA, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(SUPPL.6).
   PubMedGoogle Scholar
• Losurdo A, Rota S, Gullo G, et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. Crit Rev Oncol Hematol. 2017;113:283–291.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology. 2013 Jun 20;31(18_suppl):5-5. DOI:10.1200/jco.2013.31.18_suppl.5.
   Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209–219.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Luo W, Karlsson P, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127–138.
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Martin Jimenez M, Ring A, et al. COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease. Annals of Oncology. 2017;28(suppl_5):v74-v108. DOI:10.1093/annonc/mdx365.
   Google Scholar
• FDA expands approved use of metastatic breast cancer treatment to include male patients. [cited 2019 Jul]. https://www.pharmacist.com/article/fda-expands-approved-use-metastatic-breast-cancer-treatment-include-male-patients
   Google Scholar